Literature DB >> 19575026

Hepatosplenic T-cell lymphoma in a patient with Crohn's disease.

Florian Beigel1, Matthias Jürgens, Cornelia Tillack, Marion Subklewe, Doris Mayr, Burkhard Göke, Stephan Brand, Thomas Ochsenkühn.   

Abstract

BACKGROUND: A 58-year-old man who had a 35-year history of Crohn's disease presented to our IBD center with a disease flare, pararectal fistulas and abscess formation. The patient had previously undergone ileocolic resection for a stenosis and his abscesses had been treated by surgical drainage. He had been taking azathioprine therapy for approximately 5.5 years and had received high-dose steroids. He had also previously taken metronidazole and antihypertensive medications. INVESTIGATIONS: Physical examination, laboratory investigations including hemoglobin levels and white blood cell counts, genetic testing, CT, bone-marrow biopsy, immunophenotyping by fluorescence-activated cell sorting, polymerase chain reaction analyses, fluorescence in situ hybridization, sputum culture and diagnostic splenectomy. DIAGNOSIS: Hepatosplenic T-cell lymphoma. MANAGEMENT: Splenectomy, antibiotic therapy and chemotherapy with cyclophosphamide.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19575026     DOI: 10.1038/nrgastro.2009.87

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN: 1759-5045            Impact factor:   46.802


  15 in total

1.  In vitro and in vivo effects of 2'-deoxycoformycin (Pentostatin) on tumour cells from human gammadelta+ T-cell malignancies.

Authors:  D Aldinucci; D Poletto; V Zagonel; M Rupolo; M Degan; P Nanni; V Gattei; A Pinto
Journal:  Br J Haematol       Date:  2000-07       Impact factor: 6.998

2.  Hepatosplenic T cell lymphoma in inflammatory bowel disease.

Authors:  Matthew Shale; Ed Kanfer; Remo Panaccione; Subrata Ghosh
Journal:  Gut       Date:  2008-07-30       Impact factor: 23.059

Review 3.  Long-term survival in two patients with hepatosplenic T cell lymphoma treated with interferon-alpha.

Authors:  Michael Robert Humphreys; Maria Cino; Ian Quirt; David Barth; Vishal Kukreti
Journal:  Leuk Lymphoma       Date:  2008-07

4.  Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine.

Authors:  A Kandiel; A G Fraser; B I Korelitz; C Brensinger; J D Lewis
Journal:  Gut       Date:  2005-08       Impact factor: 23.059

5.  Hepatosplenic gammadelta T-cell lymphoma: relation to Epstein-Barr virus and activated cytotoxic molecules.

Authors:  K Ohshima; S Haraoka; N Harada; T Kamimura; J Suzumiya; M Kanda; C Kawasaki; M Sugihara; M Kikuchi
Journal:  Histopathology       Date:  2000-02       Impact factor: 5.087

6.  Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.

Authors:  Stephen B Hanauer; Brian G Feagan; Gary R Lichtenstein; Lloyd F Mayer; S Schreiber; Jean Frederic Colombel; Daniel Rachmilewitz; Douglas C Wolf; Allan Olson; Weihang Bao; Paul Rutgeerts
Journal:  Lancet       Date:  2002-05-04       Impact factor: 79.321

Review 7.  Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn's disease: a cautionary tale?

Authors:  Joel R Rosh; Thomas Gross; Petar Mamula; Anne Griffiths; Jeffrey Hyams
Journal:  Inflamm Bowel Dis       Date:  2007-08       Impact factor: 5.325

8.  A case of hepatosplenic gamma-delta T-cell lymphoma with a transient response to fludarabine and alemtuzumab.

Authors:  S Mittal; B J Milner; P W Johnston; D J Culligan
Journal:  Eur J Haematol       Date:  2006-03-17       Impact factor: 2.997

9.  Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial.

Authors:  Gert Van Assche; Charlotte Magdelaine-Beuzelin; Geert D'Haens; Filip Baert; Maja Noman; Séverine Vermeire; David Ternant; Hervé Watier; Gilles Paintaud; Paul Rutgeerts
Journal:  Gastroenterology       Date:  2008-03-08       Impact factor: 22.682

Review 10.  Hepatosplenic gammadelta T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients.

Authors:  Karim Belhadj; Felix Reyes; Jean-Pierre Farcet; Herve Tilly; Christian Bastard; Regis Angonin; Eric Deconinck; Frederic Charlotte; Veronique Leblond; Eric Labouyrie; Pierre Lederlin; Jean-Francois Emile; Beatrice Delmas-Marsalet; Bertrand Arnulf; Elie-Serge Zafrani; Philippe Gaulard
Journal:  Blood       Date:  2003-08-07       Impact factor: 22.113

View more
  11 in total

Review 1.  Mechanisms of intestinal inflammation and development of associated cancers: lessons learned from mouse models.

Authors:  Aya M Westbrook; Akos Szakmary; Robert H Schiestl
Journal:  Mutat Res       Date:  2010-03-16       Impact factor: 2.433

2.  Hepatosplenic T-cell lymphoma.

Authors:  Fahad I Alsohaibani; Maheeba A Abdulla; Mousa M Fagih
Journal:  Indian J Hematol Blood Transfus       Date:  2011-02-12       Impact factor: 0.900

3.  Systematic review: hepatosplenic T-cell lymphoma on biologic therapy for inflammatory bowel disease, including data from the Food and Drug Administration Adverse Event Reporting System.

Authors:  Eric D Shah; Elliot S Coburn; Anil Nayyar; Kerry Jo Lee; Jenna L Koliani-Pace; Corey A Siegel
Journal:  Aliment Pharmacol Ther       Date:  2020-01-28       Impact factor: 8.171

4.  Hepatosplenic T-cell lymphoma arising in patients with immunodysregulatory disorders: a study of 7 patients who did not receive tumor necrosis factor-α inhibitor therapy and literature review.

Authors:  Mariko Yabe; L Jeffrey Medeiros; Yahya Daneshbod; Masoud Davanlou; Carlos E Bueso-Ramos; Elisa J Moran; Ken H Young; Roberto N Miranda
Journal:  Ann Diagn Pathol       Date:  2016-10-18       Impact factor: 2.090

5.  Mortality associated with medical therapy versus elective colectomy in ulcerative colitis: a cohort study.

Authors:  Meenakshi Bewtra; Craig W Newcomb; Qufei Wu; Lang Chen; Fenglong Xie; Jason A Roy; Cary B Aarons; Mark T Osterman; Kimberly A Forde; Jeffrey R Curtis; James D Lewis
Journal:  Ann Intern Med       Date:  2015-08-18       Impact factor: 25.391

6.  Hepatosplenic T-cell lymphoma in a young immunocompetent man.

Authors:  Maja Petrova; Manuel Mendes Gomes; Jose Pedro Nascimento Carda; José Pereira de Moura
Journal:  BMJ Case Rep       Date:  2016-03-31

Review 7.  Optimizing the use of tumour necrosis factor inhibitors in Crohn's disease: a practical approach.

Authors:  Maria Josefina Etchevers; Ingrid Ordás; Elena Ricart
Journal:  Drugs       Date:  2010       Impact factor: 9.546

8.  A seventeen-year-old female with hepatosplenic T-cell lymphoma associated with parvoviral infection.

Authors:  Saadiya A Haque; Ying Xiang; Metin Ozdemirli; Aziza Shad; Bhaskar Kallakury
Journal:  Pediatr Rep       Date:  2010-06-18

9.  Hepatosplenic gamma-delta T-cell lymphoma in a female patient after delivery.

Authors:  Marjana Glaser; Aleš Goropevšek; Rajko Kavalar; Andrej Glaser
Journal:  Hematol Rep       Date:  2012-02-28

10.  Hepatic manifestations in hematological disorders.

Authors:  Jun Murakami; Yukihiro Shimizu
Journal:  Int J Hepatol       Date:  2013-03-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.